Skip to content
TrialScanner

NCT04671251

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1CompletedAVTXLead

Registry record

Lead sponsor
Avalo Therapeutics, Inc.
Conditions
Multiple Myeloma
Primary completion
Mar 30, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04671251 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04671251: Phase 1b Study of AEVI-007... | TrialScanner